These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33654724)

  • 1. A Radioactive-free Kinase Inhibitor Discovery Assay Against the
    Efstathiou A; Smirlis D
    Bio Protoc; 2020 Jan; 10(2):e3493. PubMed ID: 33654724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirubin Analogues Inhibit
    Efstathiou A; Gaboriaud-Kolar N; Myrianthopoulos V; Vougogiannopoulou K; Subota I; Aicher S; Mikros E; Bastin P; Skaltsounis AL; Soteriadou K; Smirlis D
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3.
    Efstathiou A; Gaboriaud-Kolar N; Smirlis D; Myrianthopoulos V; Vougogiannopoulou K; Alexandratos A; Kritsanida M; Mikros E; Soteriadou K; Skaltsounis AL
    Parasit Vectors; 2014 May; 7():234. PubMed ID: 24886176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis.
    Xingi E; Smirlis D; Myrianthopoulos V; Magiatis P; Grant KM; Meijer L; Mikros E; Skaltsounis AL; Soteriadou K
    Int J Parasitol; 2009 Oct; 39(12):1289-303. PubMed ID: 19445946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules.
    Woodland A; Grimaldi R; Luksch T; Cleghorn LA; Ojo KK; Van Voorhis WC; Brenk R; Frearson JA; Gilbert IH; Wyatt PG
    ChemMedChem; 2013 Jul; 8(7):1127-37. PubMed ID: 23776181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
    Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
    J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
    Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
    J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins.
    Knockaert M; Blondel M; Bach S; Leost M; Elbi C; Hager GL; Nagy SR; Han D; Denison M; Ffrench M; Ryan XP; Magiatis P; Polychronopoulos P; Greengard P; Skaltsounis L; Meijer L
    Oncogene; 2004 May; 23(25):4400-12. PubMed ID: 15077192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β.
    Swinney ZT; Haubrich BA; Xia S; Ramesha C; Gomez SR; Guyett P; Mensa-Wilmot K; Swinney DC
    PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004506. PubMed ID: 26942720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei.
    Faria J; Moraes CB; Song R; Pascoalino BS; Lee N; Siqueira-Neto JL; Cruz DJ; Parkinson T; Ioset JR; Cordeiro-da-Silva A; Freitas-Junior LH
    J Biomol Screen; 2015 Jan; 20(1):70-81. PubMed ID: 25342146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.
    Ojo KK; Gillespie JR; Riechers AJ; Napuli AJ; Verlinde CL; Buckner FS; Gelb MH; Domostoj MM; Wells SJ; Scheer A; Wells TN; Van Voorhis WC
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3710-7. PubMed ID: 18644955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3.
    Ojo KK; Arakaki TL; Napuli AJ; Inampudi KK; Keyloun KR; Zhang L; Hol WG; Verlinde CL; Merritt EA; Van Voorhis WC
    Mol Biochem Parasitol; 2011 Apr; 176(2):98-108. PubMed ID: 21195115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads.
    Oduor RO; Ojo KK; Williams GP; Bertelli F; Mills J; Maes L; Pryde DC; Parkinson T; Van Voorhis WC; Holler TP
    PLoS Negl Trop Dis; 2011 Apr; 5(4):e1017. PubMed ID: 21483717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioinformatic analysis of glycogen synthase kinase 3: human versus parasite kinases.
    Osolodkin DI; Zakharevich NV; Palyulin VA; Danilenko VN; Zefirov NS
    Parasitology; 2011 May; 138(6):725-35. PubMed ID: 21349219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei.
    Mackey ZB; Koupparis K; Nishino M; McKerrow JH
    Chem Biol Drug Des; 2011 Sep; 78(3):454-63. PubMed ID: 21668652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of an ESI-QTOF method for the detailed characterization of GSK-3β inhibitors.
    De Simone A; Fiori J; Naldi M; D'Urzo A; Tumiatti V; Milelli A; Andrisano V
    J Pharm Biomed Anal; 2017 Sep; 144():159-166. PubMed ID: 28268049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign.
    Diaz R; Luengo-Arratta SA; Seixas JD; Amata E; Devine W; Cordon-Obras C; Rojas-Barros DI; Jimenez E; Ortega F; Crouch S; Colmenarejo G; Fiandor JM; Martin JJ; Berlanga M; Gonzalez S; Manzano P; Navarro M; Pollastri MP
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3253. PubMed ID: 25340575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasis.
    Urich R; Grimaldi R; Luksch T; Frearson JA; Brenk R; Wyatt PG
    J Med Chem; 2014 Sep; 57(18):7536-49. PubMed ID: 25198388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS; Balaji B; Rani P; Ramanathan M
    J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei.
    Urbaniak MD; Mathieson T; Bantscheff M; Eberhard D; Grimaldi R; Miranda-Saavedra D; Wyatt P; Ferguson MA; Frearson J; Drewes G
    ACS Chem Biol; 2012 Nov; 7(11):1858-65. PubMed ID: 22908928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.